Collier P S, Riegelman S
J Pharmacokinet Biopharm. 1983 Apr;11(2):205-14. doi: 10.1007/BF01061850.
The limitations of using estimates of extent of bioavailability (F) based on the assumption that either clearance (CL) or Varea remain, constant are discussed in relation to the situation where CL changes between doses. When estimates of F assume CL to remain constant, the extent of the error is the same for all drugs where the percentage change in CL is the same. Assuming Varea to remain constant, the error in F will vary between drugs for similar percentage changes in CL and is related to the extent to which the kinetics of the disposition process deviate from a one compartment body model. A noncompartmental method is described where, provided the reference dose is given intravenously, F can be estimated based on the assumption that Vss remains constant between doses. This method is more accurate than those based on the assumption that either CL or Varea remain, constant when CL changes between doses, but is subject to error when the terminal log-linear slope of Cp vs. time better reflects the process of absorption rather than elimination.
基于清除率(CL)或血药浓度-时间曲线下面积(Varea)保持恒定这一假设来估算生物利用度(F)的范围存在局限性,本文针对不同剂量间CL发生变化的情况进行了讨论。当F的估算假设CL保持恒定时,对于CL百分比变化相同的所有药物,误差程度是相同的。假设Varea保持恒定,对于CL类似的百分比变化,不同药物的F误差会有所不同,且与处置过程动力学偏离单室模型的程度有关。本文描述了一种非房室方法,前提是静脉给予参考剂量,基于Vss在不同剂量间保持恒定的假设,可以估算F。当不同剂量间CL发生变化时,该方法比基于CL或Varea保持恒定这一假设的方法更准确,但当血药浓度(Cp)对时间的终末对数线性斜率更好地反映吸收过程而非消除过程时,该方法会产生误差。